The first COVID-19 vaccine to reach clinical trials in humans is determined to both safe and generate an immune response against the virus – a “milestone” in the battle to defeat the deadly bug, a new study to be found.
A single dose of the vaccine was found to produce antibodies against viruses and TTs, a type of immune cell, two weeks after it was administered, according to a peer-reviewed study, published Friday in the journal Lancet.
“These results represent an important practice,” said lead researcher, Professor Wei Chen.
The production of both antibodies and T cells is a good result for a vaccine, the researchers said. A vaccine that not only stimulates the body to produce viruses that are specific immune cells, but also supports the immune system̵7;s response.
But the potential vaccine is far from being available for widespread use. Further tests are needed to determine whether the vaccine effectively protects against the infection – rather than simply triggering an immune response to the virus.
“The challenges of developing a COVID-19 vaccine have not yet been met, and the ability to trigger these immune responses does not necessarily imply that the vaccine protects people from COVID-19,” he said. Chen.
“This result shows a promising outlook for developing COVID-19 vaccines, but we are still far from the vaccine available to everyone.”
The study’s authors also noted that their research was limited due to its small sample size and short duration, and it had no control group.
The study, conducted in Wuhan, China, by the Beijing Institute of Biotechnology, tested different vaccine doses in 108 healthy adults without coronavirus.
The vaccine caused no serious side effects at all doses – and allowed older adults to take it, according to research.
Two weeks later, the vaccine produced virus-resistant antibodies at all dose levels, with the highest dose level triggering antibodies in 61 percent of those taken.
Most participants also developed anti-T viruses two weeks after taking the vaccine, which was also significantly higher at higher doses.
The Beijing Institute of Biotechnology vaccine is just one of dozens of studies worldwide as public health authorities are desperately seeking a cure for pandemics, killing more than 94,000 people in the US alone.
Another promising experimental vaccine from Oxford University also reached a grand Friday, with researchers announcing that they are advancing the advanced stages of human trials of more than 10,000 volunteers.